TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00870142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose
Description: A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norvasc® 10 mg Tablets
Description: B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fasting conditions
Study: NCT04098835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASCEND
Description: ASCEND is a behavioral intervention that combines computer-based cognitive exercise, strategy coaching with a neuropsychologist, and homework exercises in order to improve attention, working memory, and cognitive control after stroke.
Study: NCT03142568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Infants will be randomized using a 3:1 scheme to receive sildenafil or placebo.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infants randomized to the placebo group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infants randomized to the placebo group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
Study: NCT02216747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone 45 mg
Description: treatment with 45 mg prednisone to compare with other arms
Study: NCT03142568

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infants randomized to the placebo group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
Study: NCT01404988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Delivered BI
Description: Behavioral Intervention will be delivered over the phone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Delivered BEI
Description: Behavioral and Environmental Intervention will be delivered over the phone
Study: NCT02216747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone 30 mg
Description: treatment with 30 mg prednisone to compare with other arms.
Study: NCT01404988

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Telephone-Delivered API
Description: Attention Placebo Intervention will be delivered over the phone
Study: NCT01066143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroquel XR
Description: Seroquel XR tablets will be flexibly dosed and begun at a target dose of 50 mg on day 1, 100 mg on day 2, 150 mg on day 3 and 200 mg on day 4 with a maximal daily dose of 400 mg on subsequent days.
Study: NCT01805505

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound-guided embryo transfer
Description: Embryo transfer of two day-3 embryos performed with the Kitazato Long ET catheter (Kitazato Medical Co. Ltd., Tokyo, Japan), guided by transvaginal ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transabdominal ultrasound-guided embryo transfer
Description: Embryo transfer of two day-3 embryos performed with the Cook Soft-Trans ET catheter (Cook Medical Inc., Bloomington, IN, USA), guided by transabdominal ultrasound
Study: NCT02095782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intercalated combination of chemotherapy and erlotinib
Description: Primary therapy stage:~Paclitaxel Patients receive six cycles of Paclitaxel (175 mg/m² on days 1 of a 4 week cycle, intravenously) plus carboplatin (AUC=5, intravenously on day 1 of a 4 week cycle, intravenously) with sequential erlotinib (150 mg/day) on days 8-21 of each cycle.~Maintenance therapy stage:~Patients, who complete 6 cycles of therapy without progression or intolerable toxicity, receive erlotinib (150 mg/day) as maintenance therapy until progression, intolerable toxicity or death.
Study: NCT03315637

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetoscopic repair of spina bifida
Description: Fetoscopic intrauterine repair of open spina bifida
Study: NCT03335527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is administered as a continuous intravenous infusion at a rate of 0.1-0.2 ug/kg/h (0.025-0.05 ml/kg/h) from study recruitment in the ICU during mechanical ventilation, for no more than 72 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Description: Placebo (normal saline) is administered as a continuous intravenous infusion at a rate of 0.025-0.05 ml/kg/h from study recruitment in the ICU during mechanical ventilation, for no more than 72 hours.
Study: NCT02950571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Picture Frame
Description: The intervention is the provision of digital picture frames in long stay inpatient rooms in a ward at CAMH.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: High level of support from an interdisciplinary team.
Study: NCT05026918

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MCPT
Description: Postural Drainagewith percussion and vibration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACBT
Description: ACBT includes Breathing control techniques, chest expansion exercises and Forced Expiration Technique
Study: NCT01680796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Dose Level 0: 200 mg daily~Dose Level 1: 300 mg daily~Dose Level 2: 300 mg daily~Dose Level 3: 400 mg daily~Dose Level 4: 500 mg daily
Study: NCT01156077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA
Description: Oral TR-701 FA 200 mg will be given as a single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA
Description: TR-701 FA 200 mg will be given as a single 60 minute IV infusion in 250 cc saline
Study: NCT00064025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01680796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Dose Level 0: 1.3 mg/m2 IV on days 1 and 8~Dose Level 1: 1.3 mg/m2 IV on days 1 and 8~Dose Level 2: 1.6 mg/m2 IV on days 1 and 8~Dose Level 3: 1.6 mg/m2 IV on days 1 and 8~Dose Level 4: 1.6 mg/m2 IV on days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg will be given orally on Days 1, 2, 8, and 9 of each 21-day cycle.
Study: NCT04146883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Post-procedural one-day iv cefazolin then 3-day prophylactic cephalexin
Study: NCT03963388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech therapy
Description: Online speech therapy, delivered by specialized speech therapists. Speech therapy will be complemented by a real-time visual feedback app (the Voice Trainer app).
Study: NCT04405570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir 200 mg
Description: Oral capsule of molnupiravir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir 400 mg
Description: Oral capsule of molnupiravir
Study: NCT00064025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone
Description: Given IM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical hysterectomy
Study: NCT03478826

Intervention type: OTHER
Intervention: ILD
Description: 100 cc of blood collected from a total of 250 ILD patients. This includes IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20)), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis

Intervention type: OTHER
Intervention: Healthy
Description: 100 cc of blood collected from a total of 25 healthy volunteers in order to compare with the ILD participants.

Intervention type: OTHER
Intervention: Pneumonia
Description: 100 cc of blood collected from a total of 100 participants with a diagnosis of pneumonia in order to compare with the ILD participants.
Study: NCT03987750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide Methanesulfonate 150mg
Description: 150 mg (free base)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide Methanesulfonate 100mg
Description: 100 mg (free base)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Safinamide Methanesulfonate matching placebo
Description: placebo
Study: NCT02095301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal Beverage
Study: NCT00707356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WST11
Description: WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/Kg,4 mg/Kg or 6 mg/kg, using 753 nm laser light at a fixed power (150mW/cm) and energy (200 J/cm) delivered through transperineal interstitial optical fibers. If deemed necessary and in consideration of the results of the patients treated with 200 J/cm, alternate power (200mW/cm) and alternate energy (300 J/cm) might be applied.The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The number of fibers and the total light energy will be adapted to each patient, taking into account the tumor localization and the volume of the prostate.
Study: NCT03035760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxfendazole
Description: methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, is a broad spectrum benzimidazole antihelminthic. It is the sulphoxide metabolite of fenbendazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxfendazole
Description: methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, is a broad spectrum benzimidazole antihelminthic. It is the sulphoxide metabolite of fenbendazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxfendazole
Description: methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, is a broad spectrum benzimidazole antihelminthic. It is the sulphoxide metabolite of fenbendazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxfendazole
Description: methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, is a broad spectrum benzimidazole antihelminthic. It is the sulphoxide metabolite of fenbendazole.
Study: NCT01397851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insecticide-treated net (BASF Incerceptor)
Description: One per farmer, once during the 2010-2011 season
Study: NCT01442298

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limb occlusion pressure (LOP)
Description: The tourniquet cuff pressure were decided by measurement of limb occlusion pressure (LOP) using an automated photo plethysmographic sensor connected to a ATS 3000 tourniquet apparatus (Zimmer Sweden Inc®).
Study: NCT04405570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir 800 mg
Description: Oral capsule of molnupiravir

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PBO)
Description: placebo oral capsule
Study: NCT04295122

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification+ Endoscopic cyclophotocoagulation (ECP) laser
Description: A clear corneal incision should be used for instrumentation. The choice of viscoelastics to maintain the anterior chamber is left to the surgeon's discretion.~Phacoemulsification energy used during the cataract surgery will be recorded. If the patient has been randomised to ECP laser, the viscoelastic will be washed-out of the capsular bag. Further cohesive viscoelastic material will be injected through the main wound between the anterior capsule and iris, until the iris is close to or touching the cornea. A curved ECP probe will be inserted through the corneal incision wound/wounds and 360° of the anterior section of the ciliary processes will be treated. The power setting will be varied according to tissue response (starting power of 250 mW with continuous setting). 'Pops' should be avoided (but recorded) but no indentation used during treatment. Final power used and duration of surgery will be recorded.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification+ Endoscopic cyclophotocoagulation (ECP) laser
Description: A clear corneal incision should be used for instrumentation. The choice of viscoelastics to maintain the anterior chamber is left to the surgeon's discretion.~Phacoemulsification energy used during the cataract surgery will be recorded. If the patient has been randomised to ECP laser, the viscoelastic will be washed-out of the capsular bag. Further cohesive viscoelastic material will be injected through the main wound between the anterior capsule and iris, until the iris is close to or touching the cornea. A curved ECP probe will be inserted through the corneal incision wound/wounds and 360° of the anterior section of the ciliary processes will be treated. The power setting will be varied according to tissue response (starting power of 250 mW with continuous setting). 'Pops' should be avoided (but recorded) but no indentation used during treatment. Final power used and duration of surgery will be recorded.
Study: NCT01175018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra 100 mg s.c. daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.67 ml of NaCl 0.9% solution given subcutaneously daily for 14 days
Study: NCT00084630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study: NCT01442298

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional measurement method
Description: Standard method at our department, the tourniquet cuff pressure was based on the patient's systolic blood pressure and a margin that were decided by the surgeon.
Study: NCT02339467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GO-OUT program
Description: Participants attend the walking workshop followed by a 3-month outdoor walking group intervention, twice weekly for 60-minutes. Each session includes a 10-minute warm-up and cool down, and a planned walk in an outdoor community environment. Continuous walking exercise will gradually increase from 10 to 60 minutes, as well increase difficulty. Balance exercises will be included in the warmup and walk. There will be a variety of surfaces and environmental factors to challenge the participants, e.g., carrying objects, diverting the walker's attention, crossing at a light, walking up and down curbs, slopes, and level or uneven surfaces. Supervision will be on a 1:3 facilitator-to-participant ratio to allow for assistance and individualization of the intervention where necessary.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Task-oriented outdoor walking workshop
Description: The 1-day workshop will be 5 hours with breaks. Participants will complete a series of stations learning information, strategies and skills related to safely walking outdoors. Stations include: pedometer use; walking pole use; footwear; footcare; fall prevention; balance exercises; proper use of walking aids; correct posture; self-management of exercise intensity; goal setting; and walking safely outdoors. Participants will receive a workbook with Canadian Physical Activity Guidelines, benefits of outdoor walking, information for each workshop station and a pedometer. Participants will use the workbook as an information resource and to record their community ambulation goals, planning routes, and walking time. All participants will be encouraged to walk outside with a partner, for safety.
Study: NCT02968355

Intervention type: OTHER
Intervention: Observational study
Description: Observational study
Study: NCT00084630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00887952

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial removal of carious dentine
Description: All procedures will be carrying out under local anesthesia and rubber dam. The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to test group: cavity floor covered with calcium hydroxide cement; restoration using amalgam or steel crown following their usual clinical procedures based on the instructions of the manufacturer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stepwise excavation
Description: The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to SE: indirect pulp capping with calcium hydroxide cement; temporary filling with IRM; cavity re-opening after 60 days, removal of the remaining soft carious tissue and filling following the same procedures described to test group.
Study: NCT02581709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Countering cognitive impairment
Description: The intervention will include education about cancer-related cognitive impairment, instruction on relaxation techniques, compensatory techniques, goal-setting and lifestyle advice. Each session will last between 90 and 120 minutes, once a week for six weeks. The intervention will be delivered in a group setting, in a non-clinical environment by the investigators.
Study: NCT02094599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol 10 mg
Description: Dronabinol at a strength equivalent to 10 mg provided in capsules or as an oral solution in syringes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol 30 mg
Description: Dronabinol at a strength equivalent to 30 mg provided in capsules or as an oral solution in syringes.
Study: NCT03625661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject
Description: Ferinject 50mg/ml, one injection
Study: NCT02094599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo provided in capsules or as an oral solution in syringes.
Study: NCT04964011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Board game intervention
Description: In this study, the two groups, the Board game group (12-week board game intervention) and Health promotion group (12-week general health promotion intervention).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Board game intervention
Description: In this study, the two groups, the Board game group (12-week board game intervention) and Health promotion group (12-week general health promotion intervention).
Study: NCT02102750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative free tafluprost opthalmic solution
Description: 0.0015% eye drops q.d, in both eyes for 7 to 9 days
Study: NCT04341051

Intervention type: OTHER
Intervention: Case
Description: Mesure with NIRS regional saturation in patients undergoing popliteal block during vascular surgery for chronic obliterating arteriopathy (IIa to III Fontaine Classification)
Study: NCT02894593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alcohol free essential oils mouthwash
Description: All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.

Intervention type: OTHER
Group type: OTHER
Intervention: alcohol essential oils mouthwash
Description: All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.20% chlorhexidine mouthwash
Description: All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
Study: NCT01151436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyaluronic acid dermal fillers
Description: 1 injection per indication and 1 touch-up injection if necessary
Study: NCT01952860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hatha Yoga
Description: 18 sessions of Hatha yoga over the course of radiation therapy. Each 45 to 60 minute session guided by an instructor. Participant should attend each session together with their caregiving partner. Some sessions videotaped. At first session, participant given a CD and instructions for practicing Hatha yoga at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion at baseline, during radiation therapy, and at completion of radiation therapy.
Study: NCT00528151

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: curcumin
Description: curcumin 250 mg twice a day in the first group. placebo 1 capsule twice a day in the second group.
Study: NCT05975229

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knitting and education (pamphlet)
Description: Pamphlet and knitting program (-8-week duration). The knitting program has two components: bi-weekly 20-minute group knitting sessions and 20-minute home daily knitting on the 5 remaining weekdays.

Intervention type: OTHER
Group type: OTHER
Intervention: Education (pamphlet)
Description: Receive only the pamphlet, not the knitting program.
Study: NCT00679887

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ischemic compression
Description: Active Comparator, ischemic compression, 3 times a week,5 weeks
Study: NCT03433625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural experiments for intolerance of uncertainty (BE-IU)
Description: CBT